Clinical characteristics of patients with stress cardiomyopathy after hip fracture
| Fracture | Age | ECG | Echocardiogram at diagnosis | Echocardiogram at discharge | Troponin I peak μg/L | ASA risk | Day from diagnosis to hip surgery |
|---|---|---|---|---|---|---|---|
| Left hip fracture | 90 | ST-segment elevation V2–V4 | Severe apical hypokinesia LVEF = 30% AVA 1,2 cm2 | LBB related septal asynchrony LVEF = 50% | 1.14 | 4 | 6 |
| Extracapsular left hip fracture | 76 | ST-segment elevation V1 - V3 | Severe apical hypokinesia LVEF = 38% | Improvement segmental wall of motion LVEF= 47% | 0.52 | 3 | 7 |
| Right hip fracture | 75 | Incomplete LBB ST-elevation V2-V4 | Anterolateral hypokinesia, and apical septal hypokinesia LVEF = 29% | Normalization of LVWM LVEF = 63% | 5.53 | 3 | 11 |
| Left hip fracture | 88 | ST-elevation V2-V6, D3, avF | Apical akinesia, anterior hypokinesia LVEF = 45% | Normalization of LVWM LVEF = 55% | 2.73 | 3 | 4 |
| Right hip fracture | 84 | Mild ST elevation V2-V5 | Akinesia of anterior septum and apex LVEF= 35%, | Normalization of LVWM LVEF =58% | 1.53 | 3 | 3 |
| Right per trochanteric fracture | 86 | Negative T waves V2-V5 | Apical akinesia LVEF =35% | Normalization of LVWM LVEF= 53% | 3.43 | 3 | 14 |
| Left hip fracture | 89 | waves Negative V3-T V6, D3, aVF | Apical akinesia LVEF= 32% | Improvement LVWM of LEVF= 48% | 0.53 | 3 | 5 |
| Right femur neck fracture | 89 | Negative T waves V2-V5 | Apical ballooning LVEF =40% | Normalization of LVWM LVEF= 58% | 0.51 | 3 | 5 |
Clinical characteristics of patients with preoperative myocardial infarction in comparison to those with stress cardiomyopathy
| Preoperative Myocardial infarction (n=43) | Stress Cardiomyopathy (n=8) | p | |
|---|---|---|---|
| Gender (F/M) | 28/15 | 8/0 | 0.08 |
| Age (years) (mean-SD) | 86.7 (7.9) | 84.7 (7.6) | 0.20 |
| Coronary heart disease | 22 | 0 | 0.007 |
| Diabetes | 24 | 2 | 0.14 |
| Hypertension | 33 | 8 | 0.09 |
| Dementia | 10 | 1 | 0.6 |
| Peripheral vascular disease | 13 | 1 | 0.4 |
| Need for RB transfusion | 15 | 5 | 0.23 |
| Double antiplatelet drug | 7 | 0 | 0.5 |
| Atrial fibrillation | 14 | 1 | 0.4 |
| Oral anticoagulation | 11 | 1 | 0.4 |
| Admission LVEF (%)(mean-SD) | 45.8 (6.3) | 35.5 (5.3) | 0.0001 |
| Troponin I peak μg/L (mean-SD) | 12.7 (4.8) | 1.96 (1.8) | 0.0001 |
| Thirty-day mortality | 5 | 0 | 0.5 |
| One-year mortality | 19 | 1 | 0.12 |
| Cause of death | |||
| Non-cardiac | 5 | 0.25 | |
| Cardiac | 15 |